{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "firstTradeDateMilliseconds": 1436940000000, "priceHint": 4, "epsTrailingTwelveMonths": -0.44, "epsForward": -0.79, "epsCurrentYear": -0.78, "priceEpsCurrentYear": -1.097436, "sharesOutstanding": 74519104, "bookValue": 0.375, "fiftyDayAverage": 1.00371, "fiftyDayAverageChange": -0.14771003, "fiftyDayAverageChangePercent": -0.14716405, "twoHundredDayAverage": 1.1789135, "twoHundredDayAverageChange": -0.32291347, "twoHundredDayAverageChangePercent": -0.2739077, "marketCap": 63788352, "forwardPE": -1.0835443, "priceToBook": 2.2826667, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 3.008428, "regularMarketPrice": 0.856, "marketState": "REGULAR", "exchange": "FRA", "shortName": "PIERIS PHARMACEUT. DL-001", "longName": "Pieris Pharmaceuticals, Inc.", "messageBoardId": "finmb_1570613", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": 0.025000036, "regularMarketTime": 1683871215, "regularMarketDayHigh": 0.856, "regularMarketDayRange": "0.856 - 0.856", "regularMarketDayLow": 0.856, "regularMarketVolume": 14000, "regularMarketPreviousClose": 0.831, "bid": 0.808, "ask": 0.84, "bidSize": 5000, "askSize": 5000, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.856, "averageDailyVolume3Month": 398, "averageDailyVolume10Day": 1837, "fiftyTwoWeekLowChange": 0.21500003, "fiftyTwoWeekLowChangePercent": 0.3354135, "fiftyTwoWeekRange": "0.641 - 2.0765", "fiftyTwoWeekHighChange": -1.2205, "fiftyTwoWeekHighChangePercent": -0.5877679, "fiftyTwoWeekLow": 0.641, "fiftyTwoWeekHigh": 2.0765, "earningsTimestamp": 1683721800, "earningsTimestampStart": 1690979400, "earningsTimestampEnd": 1691411400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "PI6.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "225 Franklin Street", "address2": "26th Floor", "city": "Boston", "state": "MA", "zip": "02110", "country": "United States", "phone": "857 246 8998", "website": "https://www.pieris.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 127, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen S. Yoder J.D.", "age": 46, "title": "CEO, Pres & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 774715, "fmt": "774.72k", "longFmt": "774,715"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas  Bures", "age": 48, "title": "Sr. VP & CFO", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 499378, "fmt": "499.38k", "longFmt": "499,378"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ahmed S. Mousa J.D.", "age": 37, "title": "Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.", "yearBorn": 1985, "fiscalYear": 2022, "totalPay": {"raw": 519784, "fmt": "519.78k", "longFmt": "519,784"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hitto  Kaufmann Ph.D.", "age": 51, "title": "Sr. VP & Chief Scientific Officer", "yearBorn": 1971, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Maria  Kelman", "title": "Exec. Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frank  Vollmering", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Shane  Olwill Ph.D.", "age": 46, "title": "Sr. VP & Chief Devel. Officer", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Prompong  Chaikul", "age": 35, "title": "Chief Supply Chain Officer", "yearBorn": 1987, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}